Urothelial Cancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028

  • Single User License $3500

Urothelial Cancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028

Status : January, 2020 | Pharmaceutical | PPT format

Report Digest

Global Urothelial Cancer Drugs Market: Overview

Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder which can spread to other parts of the body. The urothelium comprises of the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. All those comprise of the urothelial cells, or transitional cells. Urothelial carcinoma is the most widespread bladder cancer. It comprises over 90% of all bladder cancers.

The global urothelial cancer drugs market is expected to rise at a solid pace in the next couple of years with solid competition among players and the rising cases of the malignant malady. Already, nimble players are seen taking the collaboration route for development of therapies and drugs. This would likely make the global urothelial cancer drugs market crowded with new products in the next couple of years.

Global Urothelial Cancer Drugs Market: Drivers and Restraints

Mainly fuelling the global urothelial cancer drugs market is the emergence and popularity of targeted therapy. This is expected to have a major positive impact on the market in the next couple of years as well. The rapid strides made in drug targeting techniques have allowed physicians to inject drugs directly on to the bladder containing tumors. This prevents side effects of the drugs on adjacent healthy cells.

Going forward, the global urothelial cancer drugs market is predicted to see growth because of the disease progression and high recurrence rates in patients with aggressive carcinoma in-situ (CIS) classification. In the near future, the global urothelial cancer drugs market would also be boosted with better therapies being approved by prominent drug regulatory organizations. Several novel treatments are predicted to see approvals thereby further spelling opportunity for the market. Already, TECENTRIQ and OPDIVO, which are the PD-L1 inhibitors, are set to impact the market dynamics positively with their approval by the US FDA. Better knowledge about tumor immunology will likely help drug to formulate more such effective therapies in the global urothelial cancer drugs market.

Global Urothelial Cancer Drugs Market: Trends and Opportunities

The different therapies used in the global urothelial cancer drugs market are chemotherapy, intravesical therapy, and preservation therapy. Among those, chemotherapy finds application in treating invasive cancer and reducing the rate at which it spreads. In chemotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy currently generate most of the revenue in the market owing to an alarming rise in cases of bladder cancer and the rising uptake of chemotherapy to treat the same.

Global Urothelial Cancer Drugs Market: Regional Analysis

From a geographical standpoint, North America at present is a prominent contributor to revenue in the urothelial cancer drugs market. Though the market in the region is somewhat saturated and would likely rise at a slow pace in the next couple of years, it would still retain its key position. This is because of the exhaustive research on developing targeted therapies by well-established vendors domiciled in the region. Some of those are Merck and Pfizer. The U.S. is said to be mainly powering the growth in the North America urothelial cancer drugs market.  

Besides, Germany and Japan in Europe and Asia Pacific, respectively are other major contributors to the global urothelial cancer drugs market. The presence of a sizeable proportion of the target population, high uptake of novel therapies, and several product launches lined up by vendors in the nations.

Global Urothelial Cancer Drugs Market: Competitive Landscape 

Some of the key players operating in the global urothelial cancer drugs market are Roche, AstraZeneca, Merck, Pfizer, and Bristol-Myers Squibb.

The study presents reliable qualitative and quantitative insights into:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand chain of the market
  • Market valuation (revenue and/or volume)
  • Key trends/opportunities/challenges
  • Forces defining present and estimated future state of the competitive landscape
  • Technological developments
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.

Highlights of the report:

  • A detailed analysis of key segments of the market
  • Recent developments in the market’s competitive landscape
  • Detailed analysis of market segments up to second or third level of segmentation
  • Historical, current, and projected future valuation of the market in terms of revenue and/or volume
  • Key business strategies adopted by influential market vendors
  • Outline of the regulatory framework surrounding and governing numerous aspects of the market
  • Growth opportunities in emerging and established markets
  • Recommendations to market players to stay ahead of the competition

Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.

Wish to check Table of Contents of this report?

Click below to Request TOC

Request TOC